Merck Wins Nearly $2.5 Billion from Gilead in Hepatitis C Drug Royalties Verdict

Merck & Co was awarded $2.54 billion in royalties from a hepatitis C virus (HCV) drug patent lawsuit against Gilead Sciences Inc over their blockbuster HCV drugs, Sovaldi and Harvoni.

After a nearly 2-week trial, a federal jury in Delaware found that the Merck patent on these HCV drugs was valid, according to a press release.

“The jury’s verdict upholds patent protections that are essential to the development of new medical treatments,” Merck said in a statement, as reported by Fortune.

Michele Rest, spokeswoman for Gilead, said the company disagrees with the verdict and plans to appeal.

The jury’s decision was based on a 10% royalty rate from the sales of both drugs through August, Fortune reported.

On the New York Stock Exchange, Merck’s stock increased slightly to $63 in late trade, while Gilead’s shares dropped 2% to $74.06 on the NASDAQ.
 

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Direct-to-consumer prescription drug advertising increased from $1.3 billion to $6 billion over the past 20 years, particularly for high-cost biologics and cancer immunotherapies.
A recent study demonstrates the clinical benefit from the use of direct-acting antivirals for hepatitis C virus in patients with a history of liver cancer.
Doug Long, vice president of Industry Relations at IQVIA, discusses rebate reform surrounding Medicare Part D and Part B in an interview with Specialty Pharmacy Times.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$